Clinical trials: Psychosis
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with…
- Trial name
- NCT05545111
- Testing
- NBI-1117568
- Where
- 15 sites in United States
- Volunteers
- 210 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Schizophrenia, Schizoaffective Disorder
Clinical Trial of AVL-3288 in Schizophrenia Patients
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients…
- Trial name
- NCT02978599
- Testing
- AVL-3288
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in psychiatrically stable schizophrenia patients.
- Trial name
- NCT01952132
- Testing
- OMS643762
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Omeros Corporation
Schizophrenia, Schizoaffective Disorder
Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia
This research project focuses on a fundamental element of the psychopathology of schizophrenia, that is to say, the disorders of self-awareness and on the functional alterations associated with it, that is to say, self-compassion…
- Trial name
- SCE-SCHIZO (NCT05464563)
- Testing
- Electroencephalogram
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Henri Laborit
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia; Psychosis
Evaluating a Novel Mobile App for Social Cognition in Psychosis
To develop, and then evaluate a mobile phone app to deliver therapy homework activities between group sessions (social cognition intervention) in individuals with psychosis.
- Trial name
- NCT04260763
- Testing
- Social Cognition Group, Novel Mobile App
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- King's College London
Mental Disorder
Effects of a Mindfulness App for Outpatients Waitlisted for Psychological Interventions
The purpose of this study is to evaluate a mindfulness-based meditation app provided to outpatients (or community participants) who are waitlisted for standard psychological care for mental health or substance use concerns.
- Trial name
- NCT05211960
- Testing
- Mindfulness-based meditation
- Where
- Canada
- Volunteers
- 193 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia
Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
This is a prospective, non-interventional, multicentre study designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia who are suffering an acute…
- Trial name
- RESHAPE (NCT05480046)
- Testing
- Risperidone ISM
- Where
- 77 sites in Germany, Italy and 3 more
- Volunteers
- 275 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Mental Disorder
Effect of Early Assessment Team for Patients Referred to Outpatient Mental Health Care
Loss of function and incapacity for work as a result of mental disorders are increasing, especially among young people (under 30 years of age), even though the prevalence of mental illness is fairly stable.
- Trial name
- NCT05087446
- Testing
- Early assessment team, Admission to General psychiatric outpatient clinic
- Where
- Norway
- Volunteers
- 588 people
- Sponsor
- St. Olavs Hospital
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Psychosis
Optimizing Cognitive Remediation Outcomes in Schizophrenia
The purpose of this study is to drive an optimal response to neuroplasticity-based cognitive remediation in schizophrenia in order to maximize treatment response.
- Trial name
- CAST (NCT02105779)
- Testing
- Targeted Cognitive Training, Social Cognitive Training
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia.
- Trial name
- NCT00108303
- Testing
- Diagnostic
- Where
- United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.
The role of Therapeutic Drug Monitoring (TDM) in clozapine dose adjustment have been debated. Blood samples for s-clozapine monitoring should be drawn 12 hours post dose.
- Trial name
- NCT02625103
- Testing
- Blood sampling, Clozapine
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Depression, Anhedonia
Family Promoting Positive Emotions Pilot Study
Anhedonia is characterized by loss of interest or pleasure. The proposed pilot study would be the first to test an innovative, neuroscience-informed intervention in mothers reporting depressive symptoms and stress to enhance…
- Conditions
- Depression, Anhedonia, Stress, Depressive Disorder
- Trial name
- NCT05223842
- Testing
- Family Promoting Positive Emotions (F-PPE), Written Information
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Vanderbilt University
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia
Switching From Consta® to Sustenna® in Patients With Schizophrenia
The aim of this study is observation of effectiveness and side effect of patients with schizophrenia who will switch the antipsychotics from risperidone long acting injection to paliperidone palmitate.
- Trial name
- NCT01698216
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital